Fate Therapeutics, Inc. provided earnings guidance for the year 2023. For each of the remaining three quarters of 2023, the Company expects to recognize approximately $0.8 million in revenue under the ONO collaboration in connection with its conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.68 USD | -3.16% | 0.00% | -1.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.60% | 419M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023